Around 43% of all patients don’t even know that they are suffering from periodontal degeneration processes and that they have an increased need for dental hygiene measures. aMMP-8 detects these patients with a high degree of reliability and supports communication in dental hygiene to a significant extent.
The Early Detection Test
Early Detection of Active Collagen Reduction with aMMP-8
The Test System – PerioSafe Pro DRS
Most periodontal diseases develop insidiously. It may take decades for clinically manifest periodontitis to be diagnosed. That’s because, until now, the focus has been on determining the extent of the degeneration (probing depth and COP), rather than on detecting the start of collagen breakdown in the periodontal tissue.
Neue Parodontitis-Klassifikation 2018: Staging und Grading
With the introduction of a new, global classification system for periodontitis on 21 June 2018, the focus is now, more than ever, on the development and progression of periodontitis.
This comprehensive classification system incorporates the latest evidence and is based on standard WHO disease classifications, such as those for cancer. It includes a decision matrix with a “staging and grading” system for periodontitis.
Staging comprises four levels, from stage 1 (initial periodontitis) to stage 4 (advanced periodontitis). The risk of disease and the degree of disease progression are divided into three grades, from grade A (low risk or slow progression) to grade C (high risk or rapid progression).
Risk factors such as smoking and accompanying diseases like diabetes can be taken into account.
This simple yet effective approach offers a valuable opportunity to reduce the prevalence of periodontal diseases by ensuring the reliable early detection of progressive patients so that essential secondary preventive measures can be taken.
Quantitative Measurement of Progression
The aMMP-8 technology used in the PerioSafe Digital Reader System is two to three times more sensitive than the standard BOP procedure enabling a more reliable quantitative assessment of periodontal “grading” – a key progression parameter.
Detect and Measure Progression
28 Million Patients with a Greater Need for Preventive Care
Almost half of all adults in Germany are diagnosed with moderate periodontitis (grade 3) (DMS-V). Experts estimate that around 28 million German adults are in need of periodontal treatment. And yet only around one million treatments for periodontal disease were claimed from statutory health insurance companies in 2016.
In other words, only 3 to 4% of those affected are receiving suitable treatment. This discrepancy may possibly be explained by the fact that the early stage of periodontal degradation is not be detected in time or that the necessary treatment is not pursued.
For the 42,616 or so dental clinics currently operating in Germany, this means that, statistically speaking, around 657 patients per clinic could potentially be in a progressive stage of periodontitis.
PerioSafe PRO DRS – Upgrade your diagnostics
The PerioSafe PRO DRS immunological prevention diagnostic detects “progression patients” who may be in need of additional or more intensive preventive measures(e.g. shorter recall intervals for prophylaxis) in order to stabilize and preserve their oral health. As part of screening active collagen breakdown and periodontal progression can be detected in a matter of minutes with this delegable test – ideally before any visible damage occurs.
Results window
Test result can be read after just 5 minutes.
Feed opening
3 to 4 drops of the sample fluid will suffice.
Control line C
Indicates whether the test has worked correctly.
Test-Line T
Indicates the personal test result.
Increase Recall Compliance & Improve Sustainability – Prevent Tooth Loss
Personalized Prevention Requirements
Almost half of all adults in Germany are diagnosed with moderate periodontitis (grade 3) (DMS-V). Experts estimate that around 28 million German adults are in need of periodontal treatment. And yet only around one million treatments for periodontal disease were claimed from statutory health insurance companies in 2016.
In other words, only 3 to 4% of those affected are receiving suitable treatment. This discrepancy may possibly be explained by the fact that the early stage of periodontal degradation is not be detected in time or that the necessary treatment is not pursued.
As periodontal implantation processes are usually painless, patients frequently underestimate the potential health risk they present. As a result, there is a general lack of compliance and inflammation processes often progress unnoticed over many years. The personalized prevention plan helps inform patients, saves time, and improves compliance.
Patient Information Sheet
The patient information sheet explains the importance of taking appropriate preventive action to counteract active oral collagen breakdown processes (silent inflammation) effectively and as early as possible in their development.
Personalized Prevention Plan
Once you have read the exact aMMP-8 value in ng/ml (PerioSafe® PRO DRS and ORALyzer®), your patient will be able to tell which risk level (grading) applies (this is indicated in color). The patient is then fully informed about his/her personalized prevention plan and tailored dental hygiene program to minimize as far as possible the risk of oral tissue loss implant. Your personal recommendations for prevention or treatment and for optimizing care of implants at home can also be documented.
Patient Consent
By signing the Consent form, the patient consents to any interdisciplinary communication with the specialists providing his/her care that may be necessary. The patient information sheet supports risk disclosure to the patient and serves as documentation of the advice provided by the clinic.
MRT DRS Highly Sensitive Mouth-Rinse Pool Test
PerioSafe PRO DRS
| Type | Qualitative/quantitative* aMMP-8 immunoassay |
| Design | Lateral Flow Test |
| Patient Selection | The MRT test is used for the screening of preventive patients |
| Field of application | Initial early detection diagnostics |
| Goal | Identification of patients with oral silent inflammation or subclinical collagen degradation |
| What is measured? | aMMP-8 concentration in saliva (CSF) |
| Sampling | Saliva sample |
| Duration of the practice sample collection (hands-on phase) | about 2-3 minutes |
| Duration of the automatic Evaluation | 5 Min. |
| Result | POOL measurement in ng/ml from 10 ng/ml Collection result from 28 teeth |
| User group | MED & ZA |
| PSI Category | 0–1 |
| Type | Screening |
| Advantages | Particularly suitable for diagnostics in human medicine or as a supplementary basic diagnostic that can supplement PZR or GOZ No. 0010 |
| Notes and restrictions | Implantology: MRI is not suitable for implant diagnostics. Periodontology: In obvious PA cases, it is recommended to take samples from the pockets with the PST or SST test due to the more precise sampling technology directly in the inflammation area (sulcus) |
Become a PerioPrevention Center and Receive your Quality Seal
The PPC quality seal (Perio Prevention & Oral Anti-Aging Center) is the mark of quality for dental clinics that specially focus on prevention and are certified in the area of immunological diagnostic technology.
More than 300 PPCs across Europe use the latest saliva diagnostic technology to guarantee the best possible preservation of natural teeth, protection of implants, and maintenance of general health.
